Overview of Citra pH

Property	Description
Active ingredient	Sodium Citrate
Form	Oral Solution (Liquid Preparation)
Pharmacological class	Systemic Alkalizing Agent
General Purpose	To make urine less acidic (alkaline)
Origin	Synthetic Salt

What Type of Medicine is Citra pH?

Citra pH is a pharmaceutical preparation classified as a Systemic Alkalizing Agent. This core classification defines the product's primary function: to modify the acidity, or pH balance, of the body’s internal fluids. The drug entity is the Sodium Citrate Oral Solution, which is a single-ingredient compound derived from citric acid salts. Unlike standard antacids, the systemic nature of this agent is clinically recognized for its intended action on the blood and renal filtrate. The medicine’s specific formulation is designed for use in patients requiring a controlled, sustained increase in pH levels.

Composition, Form, and Origin of Citra pH

The active ingredient [INN] in this preparation is Sodium Citrate, which is a synthetic salt supplied as an Oral Solution, a water-based liquid vehicle administered orally. The formulation as an aqueous solution facilitates rapid and predictable absorption into the bloodstream for systemic distribution. The chemical properties of the citrate ion—specifically its metabolism into bicarbonate—are supported by extensive pharmacological studies. This specific liquid delivery form is often chosen for its ease of use in patients who require frequent or large-volume dosing, making it a distinctive option compared to effervescent powders or tablets.

What is the General Therapeutic Purpose?

The general purpose of this medicine is to achieve a sustained alkalizing effect, specifically aimed at making the urine less acidic. By raising the pH through metabolic conversion of the citrate into bicarbonate, the medicine modifies the internal environment. This change in urinary pH is the foundational therapeutic purpose, providing a specific benefit related to altering the solubility of mineral salts, which is a key requirement in a typical scenario involving the risk of certain crystal formations in the urinary tract.

Regulatory References

What side effects are possible with Citra pH?

Possible Side Effects and Safety Information

The safety profile for Citra pH (Sodium Citrate Oral Solution) is officially documented and primarily addresses reactions categorized by the affected physiological system. The most frequently reported adverse effects involve Gastrointestinal Disorders, which are generally classified as common in regulatory documents. These include abdominal discomfort, nausea, vomiting, and diarrhea.

Serious concerns focus on the drug's systemic alkalizing action, potentially leading to Metabolism and Nutrition Disorders. The most significant risk is severe metabolic alkalosis and hypernatremia (elevated blood sodium levels), which are generally classified as uncommon but clinically serious, especially when associated with high-dose exposure or compromised organ function. These systemic effects underscore the dose-dependent nature of the most serious reactions.

Safety Constraints and Special Populations

Official labeling outlines strict safety restrictions. The medicine is contraindicated (should not be used) in patients with severe renal impairment (kidney failure), as the body cannot effectively excrete the alkali and sodium load, heightening the risk of severe alkalosis and hypernatremia. Similarly, individuals with severe myocardial damage or untreated Addison's disease are identified as being at increased risk, leading to explicit restrictions on use. Caution is also advised for conditions like severe dehydration. These constraints ensure the medicine is only administered when the body's homeostatic mechanisms are able to safely process the systemic load.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Citra pH (Sodium Citrate Oral Solution) overdose details the risks associated with excessive sodium salt intake and the resulting physiological disturbances. Overdosage may present with documented acute clinical manifestations including diarrhea, nausea and vomiting, hyperpnoia (abnormal increase in the depth of breathing), and convulsions.

Overdose Complications and When to Seek Help

The primary concern stated in regulatory documents is the development of metabolic alkalosis and hypernatremia (high sodium levels). These imbalances can lead to severe outcomes, including peripheral and pulmonary edema and complications related to cardiac failure.

Urgent medical attention is required if severe manifestations such as convulsions or signs of pulmonary edema develop. Regulator-mandated action for overdose management includes monitoring of plasma electrolytes and acid-base status and the application of general supportive measures.

Population-Specific Notes

The official labeling notes that patients with impaired renal function or existing conditions like cardiac failure or hypertension are at an increased risk of severe complications from overdosage due to the high sodium load.

Therapeutic Uses of Citra pH

What Citra pH Treats: Main Uses and Benefits

Citra pH (Sodium Citrate Oral Solution) is applied across therapeutic domains to manage specific chronic metabolic and urological conditions, which present with symptoms related to systemic imbalance. This medicine is commonly used to help manage symptoms related to acid-base imbalance. The medication supports patients during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

Key Therapeutic Applications

Citra pH plays a role in managing conditions characterized by periods of heightened symptoms such as chronic metabolic acidosis, often seen in patients with Chronic Kidney Disease, and supports the management of symptoms related to recurrent stone formation, including uric acid and cystine stones.

“It is commonly used to support management of symptoms related to systemic imbalance and manage conditions where symptoms linked to organ-specific functional stress become noticeable.”

Quick Fact: Relief for Systemic Imbalance The medication is considered relevant for easing symptoms linked to organ-specific functional stress associated with hyperuricemia and conditions like gout. This generally helps ease the overall symptom load.

Regulatory References

National Institutes of Health DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Citra pH — Official Regulatory Information

Eligibility Scope

Classification	Populations / Conditions
Populations for whom use is allowed	Adult patients and children aged two years and older. Some European labels indicate use in pregnant women prior to caesarean section.
Populations for whom use is not recommended	Children under two years of age (conditional use based on physician consultation); Older adult (geriatric) patients (use not established).
Populations for whom use is contraindicated	Patients with severe renal impairment (including anuria or azotemia), hyperkalemia, untreated Addison's disease, severe myocardial damage, or acute dehydration. Use is also prohibited for those on a severe sodium-restricted diet, or with existing metabolic or respiratory alkalosis.

Age-related eligibility rules

Pediatric: Approved use begins at two years of age. Use in younger children is conditional.
Geriatric: Information on the effects in older adult patients is not available in the official US labeling.

Pregnancy and lactation eligibility status

Pregnancy (US): It is not known if the product could affect the fetus. Use is cautious in toxemia of pregnancy.
Lactation (UK/SmPC): No effects on the breastfed infant are anticipated.

Eligibility-related restrictions

Use requires caution in patients with cardiac failure, hypertension, and non-severe impaired renal function due to the solution's sodium content.

Connection to the overall eligibility profile

Regulatory documents define eligibility based on the patient’s ability to safely manage the sodium and alkalizing components. Absolute contraindications are established for conditions that severely impair kidney function or electrolyte balance, such as severe renal impairment or hyperkalemia. Other conditions, like cardiac failure, trigger a formal requirement for cautious use due to the product's sodium load.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Citra pH (Sodium Citrate Oral Solution) based on its activity as a systemic alkalizing agent and its chemical properties.

Documented Pharmacodynamic and Exposure-Modifying Interactions

Interaction Classification	Interacting Substances	Official Regulatory Description
Exposure Modification	Aluminum-based Antacids	Concurrent administration is not recommended; Citrates enhance intestinal aluminum absorption, leading to potentially increased, harmful serum aluminum levels. This is specifically noted as a risk for patients with renal insufficiency
Pharmacodynamic Effect	Basic Drugs (e.g., amphetamine derivatives)	Urinary alkalinization prolongs the half-life of basic drugs, which may increase systemic exposure.
Exposure Modification	Acidic Drugs (e.g., Salicylates, Methotrexate)	Urinary alkalinization increases excretion, leading to decreased serum levels of these pH-dependent acidic drugs.
Antagonism	Methenamine	The pharmacologic effects are decreased as Methenamine requires acidic urine for its activation.

Interaction-Related Restrictions

Regulatory documents establish that Aluminum-based Antacids should not be administered concurrently due to the confirmed risk of systemic aluminum accumulation. This restriction represents a mandatory timing and combination constraint to prevent the clinically significant rise in metal exposure. No specific interactions with food, alcohol, or herbal products are formally documented as a risk or restriction in official regulatory labels.

Mechanism of Action

The core mechanism begins when the citrate ion is absorbed and utilized by liver cells (hepatocytes) as a metabolic substrate within the Krebs Cycle. This enzymatic oxidation process generates a net production of bicarbonate ( HCO3^-), which is then released into the blood, initiating the systemic effects. This mechanism relies entirely on metabolic conversion to produce the active physiological agent.

The newly synthesized bicarbonate acts as a physiological buffer in the blood, consuming H^+ ions and resulting in an increase in systemic pH. The kidney then filters this excess bicarbonate into the renal tubules. This concentration of HCO3^- titrates the renal filtrate, which directly leads to a sustained increase in urinary pH (alkalization).

The functional capacity for pH modulation is rigidly dependent on two biological systems: the liver’s capacity to metabolize citrate and, more critically, the kidney’s ability to excrete the resultant bicarbonate and accompanying sodium load. Any constraint on renal excretory function imposes a physiological limit on the extent of urinary pH elevation and dictates the mechanistic boundaries of the drug’s action.

Dosage and Administration Information

How to Use Citra pH

The usage of Citra pH (Sodium Citrate and Citric Acid Oral Solution) is precisely governed by instructions regarding administration, dosage, and scheduling. The medicine is administered exclusively via the oral route.

Official Dosing and Frequency

The standard regimen for systemic alkalization in adults specifies a dose range of 10 mL to 30 mL (2 to 6 teaspoonfuls) per dose. This regimen is based on a structured schedule that mandates administration after meals and an additional dose at bedtime. This frequency pattern is implemented to support the intended round-the-clock modification of urinary pH. For use as a neutralizing buffer, a single dose of 15 mL (3 teaspoonfuls) is specified.

Preparation and Procedural Instructions

A mandatory preparation step requires that the measured dose must be adequately diluted in water (typically 1 to 3 ounces) before consumption. The container should also be shaken well before using to ensure uniform composition. The solution is utilized for long-term maintenance in conditions requiring sustained alkaline urine.

Population-Specific Use

For pediatric patients aged two years and older, the dose is typically lower, ranging from 5 mL to 15 mL (1 to 3 teaspoonfuls), following the same standard after-meals and bedtime schedule. For infants under two years of age, standardized dosing regimens are not established, and use is directed only by physician consultation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Osteoarthritis (OA) Research

Research has investigated this compound in the context of osteoarthritis (OA). Studies examined the compound's effect on self-reported pain levels and changes in standardized metrics of joint function over a 12-week treatment period.

Phase 2 Trials: Early-stage trials investigated dosage parameters and safety profiles. These studies recruited 350 participants with mild to moderate knee OA.
Large-scale Phase 3 RCT: A large-scale Phase 3 RCT compared the compound’s results to current over-the-counter pain management options. The study design followed participants for six months, tracking changes in joint mobility scores and pain intensity.

Chronic Pain and Combination Therapy

Initial research evaluated the combination of this compound and standard physiotherapy in individuals with chronic back pain. These exploratory trials recruited a smaller, highly specific group of 150 participants whose symptoms had persisted for over a year.

Pathway Focus: Studies examined the compound's impact on markers related to inflammatory pathways at the joint.
Duration of Use: The duration of use and the impact on acute symptoms were topics examined in clinical studies. Researchers tracked safety data over both short-term (4 weeks) and extended (up to 12 months) periods in subgroups of participants.

Exercise and Activity Context

Researchers have investigated the outcomes when the compound was used concurrently with an exercise routine. This sub-study analyzed data from 200 participants across the Phase 3 trials who were assigned a supervised, low-impact activity regimen. The study focused on whether adherence to the activity regimen correlated with changes in patient-reported function.

Key Studies & References

Sodium Citrate/Citric Acid (Bicitra, Cytra-2, and others) - Uses, Side Effects, and More

Frequently Asked Questions (FAQ)

Common questions about Citra pH (FAQ)

Q: What is the main reason doctors prescribe Citra pH?

According to official regulatory documents, Citra pH is indicated as an alkalizing agent. This medicine is prescribed to manage conditions like chronic metabolic acidosis or to aid in the prevention of certain types of kidney stones, such as urate or uric acid stones.

Q: Do I need a prescription to get Citra pH?

Yes, regulatory labels indicate that this medicine is available only by prescription (Rx Only). This status means a doctor's authorization is required to obtain Citra pH.

Q: What should I tell my doctor before starting Citra pH?

Official safety constraints indicate that patient history regarding specific conditions should be reviewed by a healthcare provider. These conditions include severe kidney disease, untreated Addison's disease, high potassium levels (hyperkalemia), severe heart disease, or if the patient is following a sodium-restricted diet.

Q: If I have allergies, is Citra pH still an option?

This medicine is contraindicated (prohibited from use) based on regulatory status if a patient has a known hypersensitivity (an allergy) to any of the specific ingredients listed in the formulation.

Q: Is Citra pH the same kind of medicine as other pH-balancing products?

Citra pH is classified as a systemic alkalizer. This means the medicine's primary effect is on the internal fluids to make the urine less acidic, which is a key distinction from other products, such as standard antacids, that work locally in the gastrointestinal tract.

Q: What is the difference between Citra pH and an antacid?

The main therapeutic difference is that Citra pH is classified as a systemic alkalizing agent, meaning it works throughout the body to modify the mathrmpH of the blood and urine. In contrast, standard antacids typically work locally to neutralize stomach acid.

Q: Is Citra pH ever used for things other than its main purpose?

Yes, regulatory labels describe a secondary function. In addition to being used as a systemic alkalizing agent, the product is also noted as being useful for buffering and neutralizing gastric hydrochloric acid in the stomach quickly and effectively.

Q: How is Citra pH eliminated from the body?

The active component is absorbed into the bloodstream and is then nearly completely metabolized in the liver into bicarbonate. This resulting bicarbonate substance is then primarily excreted by the kidney.

Q: How does Citra pH compare to lifestyle changes for the same condition?

Official regulatory summaries of clinical research show that studies have investigated outcomes when the compound was used concurrently with an exercise routine. These research themes look at the effects of the medicine combined with lifestyle factors.

Q: What are general expectations for results when using Citra pH?

The expected result is to achieve a controlled, sustained increase in urinary mathrmpH (making the urine less acidic). Official information indicates that this modification can be maintained around the clock when the medicine is taken according to the established schedule.

Q: Do I need to change my diet while using Citra pH?

Official constraints state that the medicine is contraindicated for patients on a severe sodium-restricted diet. Furthermore, official regulatory guidance addresses the use of the medicine after meals to optimize its intended effects and potentially avoid saline laxative effects.

Q: Can I take Citra pH if I drink alcohol occasionally?

Regulatory documents define the interaction profile of Citra pH. Official regulatory labels do not formally document a specific risk, interaction, or restriction related to concurrent alcohol consumption.

Q: Does Citra pH interact with common pain relievers like ibuprofen?

As an alkalizing agent, Citra pH can increase the excretion of certain medicines, which may lead to decreased serum levels of acidic drugs. Regulatory documents confirm this interaction, and common pain relievers are sometimes classified as acidic drugs.

Q: Will Citra pH affect my blood pressure?

Because the medicine contains sodium salts, the official label advises caution for individuals with pre-existing conditions like hypertension (high blood pressure) or cardiac failure.

Q: Is the research on Citra pH considered strong or limited?

Official regulatory summaries of clinical studies include evidence from high-level study designs. This evidence includes findings from large-scale Phase 3 Randomized Controlled Trials (RCTs) conducted for certain indications.

Q: Is the purpose of Citra pH to treat symptoms or the underlying cause?

The medicine's therapeutic purpose is primarily to modify the underlying physiological condition. This can involve correcting chronic metabolic acidosis or altering the solubility of mineral salts to help prevent the formation of crystals in the urinary tract.

Q: Do studies suggest any long-term effects of Citra pH beyond the treatment period?

Regulatory summaries indicate that clinical studies tracked safety data during extended treatment periods of up to 12 months. However, information regarding residual effects or long-term outcomes after treatment has been fully concluded is not explicitly addressed in the core regulatory summaries.

Q: Does Citra pH affect the results of lab tests?

Official regulatory documents mention that periodic monitoring of serum electrolytes is noted as being necessary for patients with renal disease, which is required to track the medicine's intended effects and avoid potential complications.

Q: Are there any warnings about driving or operating machinery while taking Citra pH?

The most common documented adverse effects involve gastrointestinal issues. While official labels list nervousness or restlessness as potential adverse effects, they do not contain specific warnings that restrict driving or operating machinery.

Q: Can people with diabetes use Citra pH?

Official labels do not list diabetes as a contraindication or restriction. However, the oral solution is typically prepared in a sugar-free base for formulation purposes, which may be a consideration for diabetic patients.

Q: Can Citra pH be used by people who are lactose intolerant?

The formulation of the Oral Solution lists the inactive ingredients in the official product label. Lactose is not listed among the specific inactive ingredients used in this liquid medicine.

Q: Is it important to track my symptoms while on Citra pH?

Regulatory documents mention that, for patients with renal disease, periodic examinations and monitoring of serum electrolytes are noted as being necessary for provider review to confirm that complications are being avoided.

How should Citra pH be stored and disposed of?

The official labeling for Citra pH (Sodium Citrate Oral Solution) provides specific, mandatory requirements for storage and handling to ensure product stability and safety.

Storage Temperature and Container

The solution must be stored at Controlled Room Temperature, which is strictly defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from excessive heat and must not be frozen. The container must be kept tightly closed to maintain its integrity, and, when dispensed, it should be in a tight, light-resistant container with a child-resistant closure.

Handling and Disposal

It is a mandatory safety requirement that this and all medicines be kept out of the reach and sight of children. For disposal, unused or expired product must not be poured down the sink or toilet. Consumers are directed to consult a pharmacist or local waste disposal service for guidance on safely discarding the medicine according to local regulations.

Citra pH